Saturday, October 31, 2026

Thousands Gathered With Jo Cox's Husband and Family to Honor her Birthday

Mark Silva

June 24, 2016

Event on birthday of Jo Cox in Trafalgar Square on 22 June 2016.
"How unbelievably lucky we were to have her in our lives for so long", said Brendan Cox, Jo Cox's widower, yesterday to crowds gathered to honor the MP’s 42nd birthday. [caption id="attachment_873" align="aligncenter" width="948"]Event on birthday of Jo Cox in Trafalgar Square on 22 June 2016. Event on birthday of Jo Cox in Trafalgar Square on 22 June 2016. Image by Andrew Davidson. CC 4.0[/caption] Mrs Cox was shot and stabbed in Birstall, in her hometown of Batley, West Yorkshire. Her sister Kim Leadbeater praised her ‘compassionate and inspirational nature." Brendan Cox cruised down the Thames on a barge with both children Lejla, three, and Cuillin, five. He delivered a heartfelt speech to a vast crowd in Trafalgar Square. It towed a memorial boat named Yorkshire Rose covered in flowers. He said: "She was the best mum any child could wish for." Meanwhile, an aircraft company apologized for flying a Leave banner over the London event. Tributes also took place in New York, Washington DC, Brussels, Melbourne and Beirut. Mr Cox said: "What a beautiful irony that an act designed for hatred brought us together in acts of love."

Categories

Tags

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com